We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Keytruda-Lenvima Combination Shows Promise in Late-Stage Trial
Keytruda-Lenvima Combination Shows Promise in Late-Stage Trial
Merck’s blockbuster oncology drug Keytruda (pembrolizumab) significantly improved survival for women suffering from endometrial cancer when combined with Eisai’s Lenvima (lenvatinib) in a late-stage clinical trial, the companies announced Friday.